Alnylam Pharmaceuticals Shares Update About Phase 3 Nucresiran Study, Reaffirms FY26 Outlook
Alnylam Pharmaceuticals (ALNY) updated its Phase 3 TRITON-CM study for nucresiran, expanding enrollment to 2,250 patients. The company aims for a 2030 launch, viewing it as key to long-term growth. Alnylam reaffirmed its FY26 outlook: $4.7B-$5.1B in product revenue, $575M-$625M in collaboration revenue, and $2.7B-$2.8B in R&D/SG&A expenses. ALNY stock fell 17.89% to $190.71.
How this was made
The 30-second read
Why it matters
The trial expansion and outlook reaffirmation suggest a longer development horizon, prompting short‑term sell‑off while preserving long‑term upside potential.
Market read
The announcement drives immediate negative sentiment for ALNY but underscores the broader risk profile of biotech trial updates.
What to watch
Potential upside from the reaffirmed FY26 revenue guidance and the long‑term growth narrative for the TTR franchise.
Background
Alnylam Pharmaceuticals (ALNY) is a leading RNAi therapeutics company with an existing portfolio targeting transthyretin amyloidosis.
Ticker impact
Alnylam announced an expanded Phase 3 TRITON-CM study for nucresiran and reaffirmed its FY26 outlook, causing the stock to drop 17.9% on the news.
likely continued pressure as the market prices in the expanded enrollment and longer path to launch
A 17.9% intraday decline indicates strong short‑term sentiment; no countervailing positive catalyst was presented.
Market effects
Highlights ongoing risk in the RNAi therapeutic space and may temper enthusiasm for similar biotech trials.
Limited to US biotech investors; no broader regional effect.
Modest, as the news pertains to a single mid‑cap biotech.
Counterpoint
The expanded trial could ultimately strengthen the data set, positioning Alnylam for a larger market opportunity if results are positive.
Key entities
- companyAlnylam Pharmaceuticals, Inc.
US‑listed biotech developing RNAi therapies.
- drug_candidatenucresiran
Next‑generation RNAi therapeutic for ATTR‑CM.
